This site is intended for healthcare professionals only
LoginRegister

Sun Pharma open to enhance manufacturing footprint in US

Written By : Ruchika Sharma   |  
No Trial Waiver: CDSCO Panel Directs Sun Pharma to Run Phase III Study for Somatropin Liquid Injection Citing Lack of India-Specific Data
  • whatsapp
  • Telegram

New Delhi: Sun Pharma has kept its options open on enhancing its manufacturing footprint in the U.S., even as the U.S. administration's 100% tariff on branded and patented medicines has created uncertainty for global drugmakers.

During an analyst call, Richard Ascroft, CEO for Sun Pharma’s North America business, said the company already has a manufacturing footprint in the U.S..

"We are kind of constantly assessing that manufacturing footprint, and we are open to considering this in the US in due time," he said, when asked if the drug maker is open to localised manufacturing in the US in the wake of high tariffs.
The company is open for all options, he said without sharing any details.
Ascroft noted that the tariff situation remains "very fluid and uncertain", and it is hard for the company to determine the impact it could have on its generics or innovative medicines portfolio at this time.
As per PTI, Sun Pharma Executive Chairman Dilip Shanghvi said the company remains on track to launch UNLOXCYT, an FDA-approved treatment for advanced skin cancer, in the US in the second half of FY26.
The company is also planning to file ILUMYA psoriatic arthritis SPLA during the second half of FY26, he added.
The company continues to invest in building a R&D pipeline of its innovative medicines business, Shanghvi stated.

Read also: Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents.

Read also: Sun Pharma appoints Jeremy Allen as Vice President, Corporate Affairs for North America

sun pharmasun pharma newsRichard AscroftDilip Shanghvi
Source : with inputs
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story
    X